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Introduction: Colonisation of the lower respiratory tract with Candida species occurs in 25% of mechanically
ventilated critically ill patients, and is associated with increased morbidity. Nebulised amphotericin B has been used
to eradicate Candida as part of selective decontamination of the digestive tract (SDD) protocols, but its
effectiveness is unknown. We aimed to determine the effectiveness of nebulised amphotericin B in eradicating
Candida respiratory tract colonisation in patients receiving SDD.
Methods: We included consecutive mechanically ventilated patients during a four-year period. Microbiological
screening was performed upon admission and twice weekly thereafter according to a standardised protocol. A
colonisation episode was defined as the presence of Candida species in two consecutive sputum samples taken at
least one day apart. To correct for time-varying bias and possible confounding, we used a multistate approach and
performed time-varying Cox regression with adjustment for age, disease severity, Candida load at baseline and
concurrent corticosteroid use.
Results: Among 1,819 patients, colonisation with Candida occurred 401 times in 363 patients; 333 of these events
were included for analysis. Decolonisation occurred in 51 of 59 episodes (86%) and in 170 of 274 episodes (62%) in
patients receiving and not receiving nebulised amphotericin B, respectively. Nebulised amphotericin B was
associated with an increased rate of Candida eradication (crude HR 2.0; 95% CI 1.4 to 2.7, adjusted HR 2.2; 95% CI
1.6 to 3.0). Median times to decolonisation were six and nine days, respectively. The incidence rate of ventilator-
associated pneumonia, length of stay and mortality did not differ between both groups.
Conclusions: Nebulised amphotericin B reduces the duration of Candida colonisation in the lower respiratory tracts
of mechanically ventilated critically ill patients receiving SDD, but data remain lacking that this is associated with a
meaningful improvement in clinical outcomes. Until more evidence becomes available, nebulised amphotericin B
should not be used routinely as part of the SDD protocol.* Correspondence: d.s.y.ong@umcutrecht.nl
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Candida species are opportunistic pathogens that ordin-
arily inhabit the human gastrointestinal tract. Colonisation
of the lower respiratory tract (LRT) by Candida occurs in
25% of critically ill patients receiving mechanical ventila-
tion and in 50% of patients suspected of ventilator-
associated pneumonia (VAP), and has been associated
with longer intensive care unit (ICU) stay, a prolonged
duration of mechanical ventilation, an increased risk of
bacterial VAP, and possibly increased in-hospital mortality
[1-4]. Whether the presence of Candida is a cause or
merely a marker of a more severe clinical course is
uncertain.
Furthermore, it remains unclear how to differentiate
between colonisation and infection of the LRT. In gen-
eral, Candida species are not assumed to be primary
causative pathogens in VAP patients [5]. In a post-
mortem study in patients with evidence of pneumonia at
autopsy, none of the subjects with a tracheal aspirate or
bronchoalveolar lavage culture positive for Candida spe-
cies had histopathological evidence of invasive Candida
growth [6]. However, there is evidence that colonisation
of the LRT by Candida species promotes the development
of pneumonia by creating biofilms that are capable of
holding other micro-organisms [7]. Moreover, Candida
is assumed to have an indirect effect by decreasing the
immune defence and favouring bacterial development
[8]. Experimental and clinical studies have shown that
Candida colonisation was associated with an increased
risk for VAP by Pseudomonas aeruginosa, and that sys-
temic antifungal treatment decreased the risk for P.
aeruginosa infection in colonised patients [1,9,10].
Side effects associated with systemic antifungal treat-
ment have limited the use of pre-emptive strategies for
Candida colonisation to patients who are at high-risk
for invasive candidiasis, such as patients with severe and
multiple-site colonisation [11]. However, local use of an-
tifungal medication may provide a potentially attractive
alternative approach. Nebulised amphotericin B (NAB)
has been used to eradicate Candida species from the
LRT as part of various selective decontamination of the
digestive tract (SDD) protocols in patients with persistent
Candida colonisation despite topical use of amphotericin
B [12]. However, the clinical effectiveness of this approach
in reducing the burden of Candida colonisation in ICU
patients is not known.
Materials and methods
Patients and measurements
This study was performed in a 32-bed mixed ICU of the
University Medical Center Utrecht in the Netherlands
between April 2008 and February 2012. The Ethics
Committee of the University Medical Center Utrecht ap-
proved this study and waived the need for informedconsent. We analysed all mechanically ventilated adults
who had been admitted to the ICU for >72 hours.
Microbiological screening for the presence of Candida
was prospectively carried out on admission and twice
weekly thereafter according to a standardised protocol
that was part of a SDD/Selective Oropharyngeal Decon-
tamination (SOD) trial [12]. In brief, samples were inoc-
ulated on malt extract agar plates, and Candida load
was semi-quantitatively determined (that is classified
as <10, 10 to 100, and >100 colony-forming units). Colon-
isation was defined as the presence of Candida species in
two or more consecutive bronchoalveolar lavage or spu-
tum samples obtained on different days in the ICU, and
the colonisation start date as the first positive sample. De-
colonisation was defined as the absence of Candida in
two consecutive samples on different days, or as the ab-
sence of Candida in the last available sample. We ex-
cluded episodes during which patients had received
systemic antifungal treatment, as well as episodes during
which NAB was initiated within the first two days after
colonisation start date (before results of microbiological
surveillance cultures had become available), because the
reason for use of amphotericin B in these cases was likely
to be different.
Decontamination protocol
All patients received either SDD (from April 2008 to
August 2009 and from June 2011 to February 2012) or
SOD (from September 2009 to May 2011). During SDD
(but not during SOD) NAB, four times 5 mg daily, was
recommended in case of Candida colonisation of the LRT
[12]. To this end, 50 mg of conventional amphotericin B
for intravenous use was dissolved in 10 mL water for in-
jection. For each nebulisation session 2 mL of water for
injection was added to 1 mL (= 5 mg amphotericin B) of
the prepared solution and aerosolised with a jet nebuliser
system (Covidien, Mansfield, MA, USA). Air or oxygen
under high pressure with a flow rate of 5 to 8 L per
minute was used to generate aerosols with a mass me-
dian aerodynamic diameter of <5 micrometer. Each
session lasted until all medication was inhaled (about
15 to 30 minutes). The nebuliser was attached to the
ventilator circuit with a T-piece adaptor positioned be-
tween the endotracheal tube and the humidification filter.
The nebulisation protocol did not recommend specific
ventilator settings. In our clinical practice, however, pa-
tients remained on a pressure-controlled ventilator with
unchanged positive end-expiratory pressure (PEEP) and
inspiratory pressure settings. Depending on the mechan-
ical ventilator type nebulisation was continuously ad-
ministered during both inspiration and expiration in
half of the NAB treatments, whereas in the remaining
cases nebulisation was only during inspiration. Alloca-
tion of a ventilator depended on availability and was
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filter in the mechanical ventilation circuit was changed
after each nebulisation session to avoid obstruction.Data analysis
Because the delay in the initiation of NAB treatment
(relative to the start of colonisation) may vary between
patients, it is important to correct for time-varying bias,
which occurs when the exposure variable is categorised
to its final status rather than considering the timing of
the change in status [13,14]. Furthermore, patients who
spontaneously decolonise early have less opportunity to
receive NAB. These cases contribute better outcomes to
the non-exposed group and therefore may lead to an
underestimation of the treatment effect. To deal with
these issues, we used time-varying Cox proportional
hazards regression with adjustment for age, Sequential
Organ Failure Assessment (SOFA) score, Candida load
at baseline, and concurrent use of corticosteroids.
In order to graphically represent the results of our
time-varying analysis and correctly estimate the median
time to decolonisation relative to the start of NAB [15],
we used the multistate model shown in Figure 1 [16].
As a secondary study outcome, we compared the in-
cidence rates of VAP occurring after the onset of the
Candida colonisation episode in both groups. For the
period 2008 to 2010, we retrospectively assessed the med-
ical records for the occurrence of VAP, according to
established CDC criteria [17]. For the period 2011 to
2012, we prospectively recorded the incidences of VAP as
part of an ongoing cohort study that is aimed at finding
early diagnostic and prognostic markers of sepsis [18].
Furthermore, we compared ICU mortality and remaining
length of stay in ICU following the onset of CandidaFigure 1 Multistate model. This multistate model was used for estimating
amphotericin B, and for graphically representing colonisation persistence prob
state as long as no treatment was given. Patients transitioned to the ‘colonisa
transitioned to ‘decolonisation with treatment’ state when decolonisation occ
treatment’ state in case decolonisation occurred without treatment or before
the remaining two states were final states in our model (meaning that no furcolonisation in patients receiving NAB compared to pa-
tients not receiving NAB.
To assess possible effect modification by the timing
of treatment, we performed a secondary analysis on the
overall treatment effect by comparing patients who had
received NAB treatment early (within five days) versus
late (after five days) following the colonisation start
date. Because of a reduced number of decolonisation
events in this subgroup analysis of early and late NAB
starters, we tested possible confounders by adding each
of them separately to a univariable Cox regression
model containing only NAB as an explanatory variable
and examining its effect on the beta coefficient of the
NAB variable on decolonisation. Covariables that
caused substantial confounding (that is a change in ef-
fect estimate greater than 10%) were included in the
final multivariable models. In addition, to assess pos-
sible indication bias we performed a per-protocol ana-
lysis of patients treated according to the SDD and SOD
arms of the trial. Data were analysed with SAS 9.2 (SAS
Institute, Inc., Cary, NC, USA) and R 2.15.1 software
(package mstate).Results
Out of a total of 1,819 patients who had been admitted to
the ICU for at least 72 hours and received mechanical
ventilation, colonisation with Candida occurred 401 times
in 363 patients (Figure 2). Colonisation rates did not differ
between the SDD and SOD periods (21% versus 19% re-
spectively, P = 0.44). After exclusion of colonisation epi-
sodes in which concurrent systemic antifungal treatment
was administered (n = 59) and episodes in which NAB
were started within the first two days after the start of col-
onisation (n = 9), 333 episodes remained for analysis.the median time to decolonisation relative to the start of nebulised
ability curves in Figure 4. A patient with colonisation remained in this
tion with treatment’ state upon receiving treatment, and subsequently
urred. The patient underwent transition to ‘decolonisation without
treatment was started. Thus, two states were transitional states, whereas
ther data were included in the model beyond this point in time).
Figure 2 Patient inclusion.







Age 63 (43–76) 63 (52–72) 0.78
Gender male 43 (73) 189 (69) 0.55
APACHE IV score 77 (60–96) 75 (58–92) 0.42
Corticosteroid usea 18 (31) 75 (27) 0.63
SOFA scoreb 6 (3–8) 5 (3–8) 0.51
Days in ICU before onset
of the colonisation episode
0 (0–2) 1 (0–3) 0.24
Candida load in sputum (CFUs)c <0.001
<10 9 (15) 117 (43)
10-100 32 (54) 102 (37)
>100 18 (31) 55 (20)
Candida colonisation of
the oropharynx
50 (85) 213 (78) 0.23
Candida colonisation of
the rectum
23 (39) 75 (27) 0.08
Delay between onset of
Candida colonisation in
sputum and NAB start
5 (4–7) NA NA
Bacterial co-colonisation
in sputum:
Gram-negative rodsd 13 (22) 83 (30) 0.20
Pseudomonas species 1 (2) 20 (7) 0.11
Gram-positive cocci 13 (22) 63 (23) 0.87
aCorticosteroid use was defined as a daily dose >100 mg hydrocortisone or
equivalent; bwe used a modified sum score, excluding points for the central
nervous system; cCandida load at baseline was determined by semi-quantitative
culture; dGram-negative rods including Pseudomonas species. APACHE, Acute
Physiology and Chronic Health Evaluation; CFU, colony-forming units; ICU,
intensive care unit; NA, not applicable; SDD, selective digestive decontamination;
SOD, selective oral decontamination; SOFA, Sequential Organ Failure Assessment.
Data are presented as medians (interquartile range (IQR)) or absolute
numbers (%).
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upon ICU admission. These patients did not have signifi-
cantly more colonisation episodes compared to patients
who acquired colonisation during the ICU admission
(P = 0.09). Overall, 44% of positive cultures were classi-
fied as Candida albicans, 11% as Candida glabrata, and
8% as non-albicans/non-glabrata/non-krusei species (37%
of cultures were not further subtyped). Concurrent oro-
pharyngeal Candida co-colonisation was present in 247
out of the 317 (78%) initial colonisation episodes, and in
10 out of the 16 (63%) recolonisation episodes.
The initial Candida load in the sputum was signifi-
cantly higher in patients receiving amphotericin B com-
pared to those not receiving therapy (Table 1). However,
the number of bacterial co-colonisations was similar in
both groups at baseline. There was also considerable
variation in the time delay between the start of Candida
colonisation and start of therapy, with 46% of patients
starting treatment after more than five days (Figure 3).
Decolonisation occurred in 51 of 59 (86%) and 170 of
274 (62%) episodes in patients receiving and not receiving
NAB, respectively. Following the start of NAB treatment
the proportion of sputum cultures growing Candida de-
creased over time (Table 2), suggesting true decolonisation
rather than in vitro suppression of growth by amphotericin.
Recolonisation occurred in 2% and 6% of patients receiving
and not receiving NAB, respectively (Table 3).
Figure 4 shows the persistence probability of colonisa-
tion as analysed using a multistate approach. Both curves
are conditioned on colonisation being present until at
least day 4. Median times to elimination of Candida were
estimated as six (interquartile range (IQR) 5 to 7) days
and nine (IQR 6 to 20) days in patients receiving and not





















Days since start of colonisation 
Early Late
Figure 3 Time delay between start of Candida colonisation and treatment initiation. This figure depicts the observed time delay between
the start of the Candida colonisation episode and the initiation of nebulised amphotericin B treatment. Episodes during which treatment was
initiated within the first two days after start of colonisation (before results of microbiological surveillance cultures had become available) were
excluded from the study, because the reason for antifungal treatment in these cases is likely to be different.
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two-fold increase in the rate of decolonisation (crude haz-
ard ratio (HR) 2.0; 95% confidence interval (CI) 1.4 to 2.7,
adjusted HR 2.2; 95% CI 1.6 to 3.0).
The incidence rate of VAP and ICU mortality did not
differ between both groups (Table 3). The length of stay
in ICU after NAB initiation was comparable to the
length of stay in ICU after onset of Candida colonisa-
tion in the control group, 14 (IQR 7 to 25) and 14 (10 to
23) days, respectively. In 5 of 59 episodes NAB treat-
ment was discontinued before successful decolonisation
was achieved, because of extubation (n = 2), clinical de-
cision to stop all antimicrobial therapy (n = 1) or unclear
reasons (n = 2). No adverse effects (such as cough or
bronchospasm) were documented in the medical records
for any of the 59 cases.Table 2 Proportion of consecutive sputum cultures
showing Candida growth following the start of nebulised
amphotericin B (NAB) treatment
Consecutive sputum cultures
following the start of NAB







There were 27/31 (87%) and 24/28 (86%) decolonisation
events in early and late NAB starters, respectively,
resulting in an adjusted HR of 2.0 (95% CI 1.3 to 3.1), and
2.0 (95% CI 1.3 to 3.2), respectively. During the SOD
period, in which NAB treatment was not recommended in
the protocol, NAB was applied in 6 of 166 (4%) cases,
whereas during the SDD period 114 of 167 (68%) cases
did not receive NAB while being colonised. However, after
exclusion of episodes during SDD in which NAB was not
started as well as episodes during SOD in which NAB was
administrated (per-protocol analysis), the effect estimates
remained similar (crude HR 2.1; 95% CI 1.4 to 3.0, ad-
justed HR 2.2; 95% CI 1.5 to 3.3).Discussion
Inhalation therapy with NAB resulted in a three-day re-
duction in the duration of Candida colonisation in the
LRT of mechanically ventilated patients who are (also)
receiving topical applications of amphotericin B as part
of a SDD protocol. This effect remained after adjustment
for potential confounders and was approximately con-
stant irrespective of the duration of colonisation prior to
the start of treatment.
Although NAB has been an essential component in
SDD protocols for many years [12,19], this is the first
study to assess the effectiveness of inhalation treatment
with NAB for eradication of Candida in colonised ICU
patients. Previous studies have focused on lung trans-
plant recipients in whom NAB was used as prophylactic
treatment for, in particular, Aspergillus infection [20-22].
Inhalation treatment seems attractive, because high drug
concentrations can be reached at the site of interest
while reducing nephrotoxicity and drug interactions
Table 3 Univariable analysis of secondary outcomes
Characteristics NAB (n = 59) Standard care
(n = 274)
P value
VAP incidence after the onset
of Candida colonisation




1 (2) 15 (6) 0.32
Length of stay in ICU after
onset of Candida colonisation
23 (12–30) 14 (10–23) 0.004
Length of stay in ICU after
NAB start
14 (7–25) NA NA
ICU Mortality 10 (17) 54 (20) 0.62
*The denominators for the calculation of the numbers of Candida recolonisation
events in the NAB and standard care group are 58 and 259 initial colonisation
episodes, respectively. ICU, intensive care unit; NA, not applicable; NAB, nebulised
amphotericin B; VAP, ventilator-associated pneumonia. Data are presented as
medians (interquartile range (IQR)) or absolute numbers (%), except for the
ventilator-associated pneumonia rate that is presented as the number per 1,000
ICU days.
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far been restricted to off-label use, due to a lack of ef-
fectiveness data and standardised methods for nebulised
administration. Although inhalation of NAB is generally
well tolerated and considered to be safe [25], various re-
ports of adverse effects, including cough, bronchospasm,


























Figure 4 Time to Candida eradication of the lower respiratory tract. Col
(NAB) group and the no NAB group were plotted with 95% confidence interv
being colonised at day 4 in order to have a meaningful comparison between
represented episodes in which NAB treatment was given and the other repreprudency [26-29]. In our study, we observed only a few
cases in which NAB treatment was discontinued before
successful decolonisation was achieved and we did not
find adverse effects documented in the medical records.
Our study has some limitations. First, the study was
performed in an SDD/SOD setting exclusively. This in-
cluded the daily application of a topical paste containing
polymyxin E, tobramycin and amphotericin B to prevent
colonisation with Gram-negative bacteria and yeasts in
the mouth. In addition, SDD (but not SOD) includes the
use of a suspension to selectively decontaminate the
digestive tract, and the systemic administration of
cefotaxime during the first four days of ICU admission
[12]. Oropharyngeal decontamination by oral paste
might influence Candida colonisation in the lower re-
spiratory tract over time by aspiration of topically ap-
plied amphotericin in the oropharynx. However, because
in both groups the topical application was entirely the
same, we assume that the estimation of the efficacy of
NAB in combination with oral paste in comparison to
oral paste alone is valid within the SDD setting. Both
SDD and SOD have been shown to effectively reduce
the incidence of VAP [19,30], therefore it is possible that
the clinical relevance of reducing the burden of Candida
colonisation by NAB treatment will differ between set-




onisation persistence probability curves of the nebulised amphotericin B
als using the multistate approach. Both curves were conditioned on
the treated and untreated patients. On any given day, one curve
sented those without treatment.
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patients eligible for this intervention according to
protocol recommendations. This probably reflects in-
dication bias. It is plausible that patients with a longer
expected ICU stay or greater disease severity were
more likely to receive NAB than patients in better
health conditions. However, we reduced the possible
effects of indication bias by excluding patients who re-
ceived NAB before microbiological results had become
available and by adjusting for potential confounding
variables, such as disease severity and Candida load.
Furthermore, we performed a per-protocol analysis
that yielded similar results. Another source of bias
may be related to the large variation in the timing of
start of treatment that was observed, also known as
immortal time bias [31]. Again, by incorporating a
time-varying approach into our analysis, we aimed to
minimise such bias.
Although we did not find a trend towards a reduced
incidence rate of VAP in patients receiving NAB, we
stress that the interpretation of this apparent lack of
clinical effectiveness requires caution, because our study
lacks the statistical power to detect potentially meaning-
ful differences in VAP rates and because of the presence
of some concurrent interventions during the use of SDD
for which we did not control.
Conclusions
Inhalation therapy with NAB is associated with a two-fold
increase in the rate of Candida decolonisation of the LRT
in mechanically ventilated patients receiving SDD,
resulting in an average reduction of the colonisation time
by approximately three days. However, we found no evi-
dence that effective decolonisation translates into a clinic-
ally meaningful reduction in VAP rates, ICU length of stay
or mortality. The routine use of NAB in current SDD pro-
tocols, therefore, cannot be recommended.
Key messages
 Inhalation therapy with nebulised amphotericin B
(NAB) is commonly used to treat colonisation of the
lower respiratory tract by Candida species as part of
SDD/SOD protocols, but its effectiveness has not
been studied.
 NAB therapy reduces the duration of Candida
colonisation of the lower respiratory tract by
approximately three days. However, the incidence
rate of ventilator-associated pneumonias was not
different between the two groups.
 Even without NAB treatment most patients seem to
spontaneously decolonise eventually, possibly due
the topical application in the oropharynx as part of
SDD/SOD. Given the current state of evidence, NAB should not
be used routinely as part of SDD.
Abbreviations
CI: Confidence interval; HR: Hazard ratio; ICU: Intensive care unit;
IQR: Interquartile range; LRT: lower respiratory tract; NAB: Nebulised
amphotericin B; SDD: Selective digestive decontamination; SOD: Selective
oral decontamination; VAP: Ventilator-associated pneumonia.
Competing interests
This research was performed within the framework of CTMM, the Center for
Translational Molecular Medicine (http://www.ctmm.nl), project MARS (grant
04I-201). Marc Bonten has received research funding from the Netherlands
Organization of Scientific Research (NWO Vici 918.76.611).
Authors’ contributions
DO, PK, CS, MB and OC substantially contributed to the conception and
design of this study. DO, PK and OC acquired the data. DO and CS
performed the data analyses. DO, PK, CS, MB and OC were involved in the
interpretation of data. DO drafted the manuscript and all authors revised it
critically for important intellectual content. All authors read and approved
the final manuscript.
Acknowledgements
We thank Karen Vlaardingerbroek and Sandra Numan, from the Department
of Intensive Care Medicine, UMC Utrecht, for their assistance in data
acquisition.
Author details
1Department of Intensive Care Medicine, University Medical Center Utrecht,
Heidelberglaan 100, 3584, CX Utrecht, The Netherlands. 2Department of
Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100,
3584, CX Utrecht, The Netherlands. 3Julius Center for Health Sciences and
Primary Care, University Medical Center Utrecht, Heidelberglaan 100, 3584,
CX Utrecht, The Netherlands. 4Department of Mathematics, Utrecht
University, Budapestlaan 6, 3584, CD Utrecht, The Netherlands.
Received: 9 April 2013 Accepted: 4 September 2013
Published: 11 October 2013
References
1. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C,
Garrouste-Orgeas M, Cohen Y, Mourvillier B, Schlemmer B: Candida
colonization of the respiratory tract and subsequent pseudomonas
ventilator-associated pneumonia. Chest 2006, 129:110–117.
2. Delisle MS, Williamson DR, Perreault MM, Albert M, Jiang X, Heyland DK: The
clinical significance of Candida colonization of respiratory tract
secretions in critically ill patients. J Crit Care 2008, 23:11–17.
3. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP, Charles PE:
Candida spp. airway colonization could promote antibiotic-resistant
bacteria selection in patients with suspected ventilator-associated
pneumonia. Intensive Care Med 2012, 38:1272–1279.
4. Olaechea PM, Palomar M, Leon-Gil C, Alvarez-Lerma F, Jorda R, Nolla-Salas J,
León-Regidor MA, et al: Economic impact of Candida colonization and
Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis
2004, 23:323–330.
5. Ricard JD, Roux D: Candida pneumonia in the ICU: myth or reality?
Intensive Care Med 2009, 35:1500–1502.
6. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE,
Van Wijngaerden E: Significance of the isolation of Candida species from
airway samples in critically ill patients: a prospective, autopsy study.
Intensive Care Med 2009, 35:1526–1531.
7. El-Azizi MA, Starks SE, Khardori N: Interactions of Candida albicans with
other Candida spp. and bacteria in the biofilms. J Appl Microbiol 2004,
96:1067–1073.
8. Ricard JD, Roux D: Candida colonization in ventilated ICU patients: no
longer a bystander! Intensive Care Med 2012, 38:1243–1245.
9. Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di PC, Dewavrin F, Favory R,
Roussel-Delvallez M, Durocher A: Impact of antifungal treatment on
Candida-Pseudomonas interaction: a preliminary retrospective case-
control study. Intensive Care Med 2007, 33:137–142.
Ong et al. Critical Care 2013, 17:R233 Page 8 of 8
http://ccforum.com/content/17/5/R23310. Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, Saumon
G, Ricard JD: Candida albicans impairs macrophage function and
facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med
2009, 37:1062–1067.
11. Lam SW, Eschenauer GA, Carver PL: Evolving role of early antifungals in
the adult intensive care unit. Crit Care Med 2009, 37:1580–1593.
12. de Smet AM, Kluytmans JA, Cooper BS, Mascini EM, Benus RF, van der Werf
TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJ,
Bernards AT, Kuijper EJ, Joore JC, Leverstein-van Hall MA, Bindels AJ, Jansz
AR, Wesselink RM, de Jongh BM, Dennesen PJ, van Asselt GJ, te Velde LF,
Frenay IH, Kaasjager K, Bosch FH, van Iterson M, Thijsen SF, Kluge GH, Pauw
W, de Vries JW, Kaan JA, et al: Decontamination of the digestive tract and
oropharynx in ICU patients. N Engl J Med 2009, 360:20–31.
13. Shintani AK, Girard TD, Eden SK, Arbogast PG, Moons KG, Ely EW: Immortal
time bias in critical care research: application of time-varying Cox
regression for observational cohort studies. Crit Care Med 2009,
37:2939–2945.
14. Suissa S: Effectiveness of inhaled corticosteroids in chronic obstructive
pulmonary disease: immortal time bias in observational studies. Am J
Respir Crit Care Med 2003, 168:49–53.
15. Simon R, Makuch RW: A non-parametric graphical representation of the
relationship between survival and the occurrence of an event:
application to responder versus non-responder bias. Stat Med 1984,
3:35–44.
16. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: competing risks
and multi-state models. Stat Med 2007, 26:2389–2430.
17. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of
health care-associated infection and criteria for specific types of
infections in the acute care setting. Am J Infect Control 2008, 36:309–332.
18. Klein Klouwenberg PM, Ong DS, Bos LD, de Beer FM, van Hooijdonk RT,
Huson MA, Straat M, van Vught LA, Wieske L, Horn J, Schultz MJ, van der
Poll T, Bonten MJ, Cremer OL: Interobserver agreement of centers for
disease control and prevention criteria for classifying infections in
critically Ill patients. Crit Care Med 2013, 41:2373–2378.
19. de Jonge E, Schultz MJ, Spanjaard L, Bossuyt PM, Vroom MB, Dankert J,
Kesecioglu J: Effects of selective decontamination of digestive tract on
mortality and acquisition of resistant bacteria in intensive care: a
randomised controlled trial. Lancet 2003, 362:1011–1016.
20. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP: A survey of
anti-fungal management in lung transplantation. J Heart Lung Transplant
2004, 23:1376–1381.
21. Koo S, Kubiak DW, Issa NC, Dietzek A, Boukedes S, Camp PC, Goldberg HJ,
Baden LR, Fuhlbrigge AL, Marty FM: A targeted peritransplant antifungal
strategy for the prevention of invasive fungal disease after lung
transplantation: a sequential cohort analysis. Transplantation 2012,
94:281–286.
22. Monforte V, Ussetti P, Lopez R, Gavalda J, Bravo C, de Pablo A, Pou L,
Pahissa A, Morell F, Román A: Nebulized liposomal amphotericin B
prophylaxis for Aspergillus infection in lung transplantation:
pharmacokinetics and safety. J Heart Lung Transplant 2009, 28:170–175.
23. Dhand R: The role of aerosolized antimicrobials in the treatment of
ventilator-associated pneumonia. Respir Care 2007, 52:866–884.
24. Dolovich MB, Dhand R: Aerosol drug delivery: developments in device
design and clinical use. Lancet 2011, 377:1032–1045.
25. Kuiper L, Ruijgrok EJ: A review on the clinical use of inhaled amphotericin
B. J Aerosol Med Pulm Drug Deliv 2009, 22:213–227.
26. Drew RH, Dodds AE, Benjamin DK Jr, Duane DR, Palmer SM, Perfect JR:
Comparative safety of amphotericin B lipid complex and amphotericin B
deoxycholate as aerosolized antifungal prophylaxis in lung-transplant
recipients. Transplantation 2004, 77:232–237.
27. Dubois J, Bartter T, Gryn J, Pratter MR: The physiologic effects of inhaled
amphotericin B. Chest 1995, 108:750–753.
28. Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, et al: Safety of
aerosolized liposomal versus deoxycholate amphotericin B formulations
for prevention of invasive fungal infections following lung
transplantation: a retrospective study. Transpl Infect Dis 2007, 9:121–125.
29. Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O’Toole K, Williams
SF, Larson RA, Geller RB: A pilot study of prophylactic aerosolized
amphotericin B in patients at risk for prolonged neutropenia.
Leuk Lymphoma 1992, 8:229–233.30. Bergmans DC, Bonten MJ, Gaillard CA, Paling JC, van der Geest S, van Tiel
FH, Beysens AJ, de Leeuw PW, Stobberingh EE: Prevention of ventilator-
associated pneumonia by oral decontamination: a prospective,
randomized, double-blind, placebo-controlled study. Am J Respir Crit Care
Med 2001, 164:382–388.
31. Levesque LE, Hanley JA, Kezouh A, Suissa S: Problem of immortal time bias
in cohort studies: example using statins for preventing progression of
diabetes. BMJ 2010, 340:b5087.
doi:10.1186/cc13056
Cite this article as: Ong et al.: Nebulised amphotericin B to eradicate
Candida colonisation from the respiratory tract in critically ill patients
receiving selective digestive decontamination: a cohort study. Critical
Care 2013 17:R233.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
